ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CBAY Cymabay Therapeutics Inc

32.48
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cymabay Therapeutics Inc NASDAQ:CBAY NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 32.48 34.10 30.85 0 01:00:00

Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm

12/02/2024 6:43pm

PR Newswire (US)


Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart


From Feb 2024 to May 2024

Click Here for more Cymabay Therapeutics Charts.

NEW YORK, Feb. 12, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.  Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. 

Kuehn Law, PLLC (PRNewsfoto/Kuehn Law, PLLC)

Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: 

  • Ambrx Biopharma, Inc. (Nasdaq: AMAM) click to participate

Ambrx Biopharma has agreed to be acquired by Johnson & Johnson. Under the agreement, shareholders of Ambrx will be entitled to a payment of $28.00 per share in cash.

  • Masonite International Corporation (NYSE: DOOR) click to participate

Masonite has agreed to be acquired by Owens Corning. Under the agreement, shareholders of Masonite will be entitled to a payment of $133.00 per share in cash.

  • CymaBay Therapeutics, Inc. (Nasdaq: CBAY) click to participate

CymaBay Therapeutics has agreed to be acquired by Gilead Sciences. Under the agreement, shareholders of CymaBay Therapeutics will be entitled to a payment of $32.50 per share in cash.

  • ContextLogic Inc. (Nasdaq: WISH) click to participate

ContextLogic has agreed to be acquired by Qoo10. Under the agreement, shareholders of ContextLogic will be entitled to a payment of $6.50 per share in cash.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.

How to Get Involved:

Kuehn Law is dedicated to safeguarding shareholder interests. Concerned shareholders are encouraged to contact Justin Kuehn, Esq., at justin@kuehn.law or call (833) 672-0814. Kuehn Law covers all case costs and does not charge its investor clients.  Shareholders are advised to act promptly, as legal rights may be time-sensitive. For additional information, please visit Merger Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-amam-door-cbay-and-wish-investors-to-contact-law-firm-302059770.html

SOURCE Kuehn Law, PLLC

Copyright 2024 PR Newswire

1 Year Cymabay Therapeutics Chart

1 Year Cymabay Therapeutics Chart

1 Month Cymabay Therapeutics Chart

1 Month Cymabay Therapeutics Chart

Your Recent History

Delayed Upgrade Clock